Index of reports
> Cases with Myocardial Infarction (5)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vesanoid (Tretinoin Oral) where reactions include myocardial infarction. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Vesanoid side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-03-22
Patient:
Reactions: Acute Promyelocytic Leukaemia Differentiation Syndrome, Guillain-Barre Syndrome, Haemorrhage, Pyrexia, Death, Renal Failure, Benign Intracranial Hypertension, Embolism, Neutropenia, Myocardial Infarction, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Vesanoid
Dosage: induction: until complete remission or for maximum 45 days.
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: high risk: course 1: days 1-4.
Indication: Acute Promyelocytic Leukaemia
Idarubicin Hydrochloride
Dosage: consolidation therapy: course 3: on day 1
Idarubicin Hydrochloride
Dosage: induction therapy: on days 2, 4, 6 and 8.
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: high risk: course 3: days 1-5
Etoposide
Dosage: consolidation: high risk: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Vesanoid
Dosage: consolidation therapy
Administration route: Oral
Mitoxantrone Hydrochloride
Dosage: consolidation: high and low/intermediate risk: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Thioguanine
Dosage: consolidation: high risk: course 3: days 1-5
Indication: Acute Promyelocytic Leukaemia
Idarubicin Hydrochloride
Dosage: consolidation course 1: on days 1, 2, 3 and 4
Other drugs received by patient: Prednisone TAB
Possible Vesanoid side effects in
Reported by a individual with unspecified qualification from Italy on 2012-03-18
Patient:
Reactions: Guillain-Barre Syndrome, Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Benign Intracranial Hypertension, Renal Failure, Embolism, Neutropenia, Myocardial Infarction, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cytarabine
Dosage: consolidation: high risk: course 1: days 1-4.
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: high risk: course 3: days 1-5
Vesanoid
Dosage: consolidation therapy
Administration route: Oral
Thioguanine
Dosage: consolidation: high risk: course 3: days 1-5
Indication: Acute Promyelocytic Leukaemia
Vesanoid
Dosage: induction: until complete remission or for maximum 45 days.
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: consolidation course 1: on days 1, 2, 3 and 4
Idarubicin HCL
Dosage: consolidation therapy: course 3: on day 1
Etoposide
Dosage: consolidation: high risk: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone Hydrochloride
Dosage: consolidation: high and low/intermediate risk: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: induction therapy: on days 2, 4, 6 and 8.
Indication: Acute Promyelocytic Leukaemia
Other drugs received by patient: Prednisone
Possible Vesanoid side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-03-18
Patient:
Reactions: Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Retinoic Acid Syndrome, Renal Failure, Benign Intracranial Hypertension, Embolism, Neutropenia, Myocardial Infarction, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Etoposide
Dosage: consolidation: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: induction therapy: on days 2, 4, 6 and 8.
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: course 1: days 1-4.
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: course 3: days 1-5
Idarubicin HCL
Dosage: consolidation course 1: on days 1, 2, 3 and 4
Vesanoid
Dosage: induction: until complete remission or for maximum 45 days.
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: consolidation therapy: course 3: on day 1
Mitoxantrone Hydrochloride
Dosage: consolidation: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Thioguanine
Dosage: consolidation: course 3: days 1-5
Indication: Acute Promyelocytic Leukaemia
Other drugs received by patient: Prednisone
Possible Vesanoid side effects in
Reported by a individual with unspecified qualification from Italy on 2012-03-13
Patient:
Reactions: Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Retinoic Acid Syndrome, Benign Intracranial Hypertension, Renal Failure, Embolism, Neutropenia, Myocardial Infarction, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Idarubicin HCL
Dosage: consolidation therapy: course 3: on day 1
Cytarabine
Dosage: consolidation: course 3: days 1-5
Vesanoid
Dosage: induction: until complete remission or for maximum 45 days.
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Mitoxantrone Hydrochloride
Dosage: consolidation: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: induction therapy: on days 2, 4, 6 and 8.
Indication: Acute Promyelocytic Leukaemia
Idarubicin HCL
Dosage: consolidation course 1: on days 1, 2, 3 and 4
Etoposide
Dosage: consolidation: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: course 1: days 1-4.
Indication: Acute Promyelocytic Leukaemia
Thioguanine
Dosage: consolidation: course 3: days 1-5
Indication: Acute Promyelocytic Leukaemia
Other drugs received by patient: Prednisone
Possible Vesanoid side effects in
Reported by a individual with unspecified qualification from Italy on 2012-03-02
Patient:
Reactions: Guillain-Barre Syndrome, Acute Promyelocytic Leukaemia Differentiation Syndrome, Haemorrhage, Pyrexia, Death, Benign Intracranial Hypertension, Renal Failure, Embolism, Neutropenia, Myocardial Infarction, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Vesanoid
Dosage: consolidation therapy
Administration route: Oral
Idarubicin Hydrochloride
Dosage: consolidation therapy: course 3: on day 1
Idarubicin Hydrochloride
Dosage: induction therapy: on days 2, 4, 6 and 8.
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: high risk: course 3: days 1-5
Idarubicin Hydrochloride
Dosage: consolidation course 1: on days 1, 2, 3 and 4
Mitoxantrone Hydrochloride
Dosage: consolidation: high and low/intermediate risk: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Thioguanine
Dosage: consolidation: high risk: course 3: days 1-5
Indication: Acute Promyelocytic Leukaemia
Vesanoid
Dosage: induction: until complete remission or for maximum 45 days.
Administration route: Oral
Indication: Acute Promyelocytic Leukaemia
Cytarabine
Dosage: consolidation: high risk: course 1: days 1-4.
Indication: Acute Promyelocytic Leukaemia
Etoposide
Dosage: consolidation: high risk: course 2: days 1-5
Indication: Acute Promyelocytic Leukaemia
Other drugs received by patient: Prednisone TAB
|